- Home
- CVBF vs RYTM Comparison
CVBF vs RYTM Comparison
Compare CVBF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVBF
- RYTM
- Stock Information
- Founded
- CVBF 1974
- RYTM 2008
- Country
- CVBF United States
- RYTM United States
- Employees
- CVBF N/A
- RYTM N/A
- Industry
- CVBF Major Banks
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CVBF Finance
- RYTM Health Care
- Exchange
- CVBF Nasdaq
- RYTM Nasdaq
- Market Cap
- CVBF 3.3B
- RYTM 3.1B
- IPO Year
- CVBF N/A
- RYTM 2017
- Fundamental
- Price
- CVBF $22.65
- RYTM $55.56
- Analyst Decision
- CVBF Hold
- RYTM Strong Buy
- Analyst Count
- CVBF 6
- RYTM 10
- Target Price
- CVBF $21.80
- RYTM $63.70
- AVG Volume (30 Days)
- CVBF 750.7K
- RYTM 470.5K
- Earning Date
- CVBF 01-22-2025
- RYTM 11-05-2024
- Dividend Yield
- CVBF 3.54%
- RYTM N/A
- EPS Growth
- CVBF N/A
- RYTM N/A
- EPS
- CVBF 1.42
- RYTM N/A
- Revenue
- CVBF $518,203,999.00
- RYTM $112,530,000.00
- Revenue This Year
- CVBF N/A
- RYTM $63.64
- Revenue Next Year
- CVBF $2.34
- RYTM $42.98
- P/E Ratio
- CVBF $15.90
- RYTM N/A
- Revenue Growth
- CVBF N/A
- RYTM 81.55
- 52 Week Low
- CVBF $15.71
- RYTM $35.17
- 52 Week High
- CVBF $24.58
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- CVBF 52.83
- RYTM 45.40
- Support Level
- CVBF $22.32
- RYTM $54.52
- Resistance Level
- CVBF $23.19
- RYTM $58.56
- Average True Range (ATR)
- CVBF 0.62
- RYTM 1.90
- MACD
- CVBF -0.20
- RYTM -0.65
- Stochastic Oscillator
- CVBF 27.93
- RYTM 21.10
About CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.